ResMed Inc. (RMD)
ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities
ResMed Inc. RMD reported fourth-quarter 2024 revenue of $1.22 billion, up 9% year-over-year and up 10% on a constant currency basis, in line with the consensus of $1.22 billion.
ResMed's (RMD) Q4 Earnings Surpass Estimates, Margins Expand
ResMed (RMD) delivers solid performance across all regions and business segments in the fourth quarter of fiscal 2024.
Lost Money on ResMed Inc. (RMD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
ResMed Inc. (RMD) Q4 2024 Earnings Call Transcript
ResMed Inc. (NYSE:RMD ) Q4 2024 Earnings Conference Call August 031, 2024, 04:30 PM ET Company Participants Amy Wakeham - Chief Communications and Investor Relations Officer Michael Farrell - Chief Executive Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Lyanne Harrison - Bank of America Steven Wheen - Jarden Brett Fishbin - KeyBanc Michael Matson - Needham & Company Dan Hurren - MST Marquee David Bailey - Macquarie Gretel Janu - E&P Suraj Kalia - Oppenheimer Margaret Kaczor-Andrew - William Blair Anthony Petrone - Mizuho Group Saul Hadassin - Barrenjoey Capital Operator Hello, and welcome to the Q4 Fiscal Year 2024 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call.
Compared to Estimates, ResMed (RMD) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ResMed (RMD) Beats Q4 Earnings and Revenue Estimates
ResMed (RMD) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.60 per share a year ago.
ResMed meets estimates on steady demand for its sleep apnea devices
Medical equipment maker ResMed reported fourth-quarter revenue in line with estimates on Thursday, on steady demand for its sleep apnea treatment devices.
RMD ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of ResMed Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
Why ResMed (RMD) is Poised to Beat Earnings Estimates Again
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Levi & Korsinsky Reminds ResMed Investors of the Ongoing Investigation into Potential Violations of Securities Laws - RMD
NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
Seeking Clues to ResMed (RMD) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of ResMed (RMD) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
